Breaking News Instant updates and real-time market news.

CLLS

Cellectis

$31.65

-1.47 (-4.44%)

16:32
03/13/18
03/13
16:32
03/13/18
16:32

Cellectis COO Simon to retire, Boglioli named successor

Cellectis announced that Dr. Mathieu Simon is retiring as Executive Vice President and Chief Operating Officer, effective immediately. Following a smooth and successful transition over the last few months, Elsy Boglioli, Executive Vice President, Strategy and Corporate Development, is named Chief Operating Officer. Mathieu Simon has served as Cellectis' Executive Vice President since 2012 and as Chief Operating Officer since 2013. He was a member of Cellectis' board of directors as well.

  • 04

    Apr

CLLS Cellectis
$31.65

-1.47 (-4.44%)

09/05/17
RHCO
09/05/17
DOWNGRADE
RHCO
Hold
Cellectis downgraded to Hold from Buy at SunTrust
09/05/17
FBCO
09/05/17
NO CHANGE
FBCO
Outperform
No read through to Gilead, Kite from Cellectis clinical hold, says Credit Suisse
Credit Suisse analyst Alethia Young said the safety issues that Cellectis (CLLS) is encountering, and which prompted a clinical hold be placed on the company's allogenic CAR-T drug, UCART123, could be to some degree related to the company's platform. She adds that CRS, which led to a death in Cellectis' BPDCN study, is a known issue with CAR-T technologies and cases have been seen in Juno (JUNO) and Kite's (KITE) programs as well. The analyst, who doesn't think there is a read through to Kite and Gilead (GILD) from the Cellectis news and remains confident Kite will receive approval later this fall and launch Axi-Cel, keeps an Outpeform rating on Gilead shares.
09/06/17
RHCO
09/06/17
DOWNGRADE
RHCO
Hold
Cellectis downgraded on patient death, study halt at SunTrust
As noted earlier, SunTrust downgraded Cellectis to Hold from Buy. Analyst Peter Lawson downgraded the stock after a patient died during the company's BPDCN study, leading the FDA to place a clinical hold on both Phase 1 studies of Cellectis' UCART123, a CAR-T drug. Target to $20 from $35.
12/28/17
OPCO
12/28/17
NO CHANGE
Target $40
OPCO
Outperform
Oppenheimer remains bullish on Cellectis
Oppenheimer analyst Hartaj Singh highlights Cellectis as a high-conviction idea. The analyst argues that the technical and development hurdles that the company must singularly solve for each product also creates a high barrier to entry. As the 60/40 divide between autologous/allogeneic bone marrow transplant - the closest analog to CAR-T currently - demonstrates, the scarcity value of Cellectis' approach may not be reflected in its current share price. Singh stays bullish, and reiterates an Outperform rating and $40 price target on the shares.

TODAY'S FREE FLY STORIES

KMX

CarMax

07:42
12/14/18
12/14
07:42
12/14/18
07:42
Recommendations
CarMax analyst commentary  »

Wedbush…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 21

    Dec

AMD

AMD

$19.86

-0.63 (-3.07%)

, NVDA

Nvidia

$148.88

-0.02 (-0.01%)

07:42
12/14/18
12/14
07:42
12/14/18
07:42
Recommendations
AMD, Nvidia analyst commentary  »

Mizuho cuts AMD target to…

AMD

AMD

$19.86

-0.63 (-3.07%)

NVDA

Nvidia

$148.88

-0.02 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

  • 08

    Jan

  • 08

    Jan

SUP

Superior Industries

$5.94

-0.21 (-3.41%)

07:39
12/14/18
12/14
07:39
12/14/18
07:39
Hot Stocks
Superior Industries CEO Don Stebbins to retire »

Superior Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$170.93

1.84 (1.09%)

07:39
12/14/18
12/14
07:39
12/14/18
07:39
Periodicals
Notable Apple analyst cuts iPhone shipment estimate by 20%, CNBC says »

Demand for iPhones is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$34.90

2.765 (8.60%)

07:38
12/14/18
12/14
07:38
12/14/18
07:38
Downgrade
Ciena rating change  »

Ciena downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$34.90

2.765 (8.60%)

07:36
12/14/18
12/14
07:36
12/14/18
07:36
Recommendations
Ciena analyst commentary  »

Ciena price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$24.39

-0.14 (-0.57%)

, C

Citi

$55.77

-0.22 (-0.39%)

07:35
12/14/18
12/14
07:35
12/14/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BAC

Bank of America

$24.39

-0.14 (-0.57%)

C

Citi

$55.77

-0.22 (-0.39%)

JD

JD.com

$22.71

0.81 (3.70%)

WFC

Wells Fargo

$47.03

-0.72 (-1.51%)

M

Macy's

$30.80

-1.0425 (-3.27%)

SBUX

Starbucks

$66.90

0.8 (1.21%)

CLF

Cleveland-Cliffs

$8.23

-0.135 (-1.61%)

MET

MetLife

$39.52

-0.05 (-0.13%)

NWL

Newell Brands

$22.78

-0.785 (-3.33%)

MRVL

Marvell

$15.64

0.29 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 06

    Jan

  • 08

    Jan

  • 14

    Jan

  • 15

    Jan

  • 12

    Feb

  • 12

    Apr

  • 15

    Apr

  • 18

    Jun

  • 13

    Jul

  • 13

    Jul

  • 12

    Oct

ICLR

Icon

$136.31

-1.83 (-1.32%)

07:34
12/14/18
12/14
07:34
12/14/18
07:34
Downgrade
Icon rating change  »

Icon downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORTX

Orchard Therapeutics

$15.01

-0.29 (-1.90%)

07:33
12/14/18
12/14
07:33
12/14/18
07:33
Hot Stocks
Orchard Therapeutics, SIRION Biotech enter license agreement for LentiBOOST »

Orchard Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$16.33

-0.24 (-1.45%)

07:32
12/14/18
12/14
07:32
12/14/18
07:32
Downgrade
Amneal Pharmaceuticals rating change  »

Amneal downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GE

General Electric

$7.20

0.48 (7.14%)

, OSTK

Overstock.com

$17.97

-1.13 (-5.92%)

07:30
12/14/18
12/14
07:30
12/14/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$7.20

0.48 (7.14%)

OSTK

Overstock.com

$17.97

-1.13 (-5.92%)

GME

GameStop

$12.79

-0.445 (-3.36%)

ESRX

Express Scripts

$98.94

2.03 (2.09%)

CC

Chemours

$27.15

0.485 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:30
12/14/18
12/14
07:30
12/14/18
07:30
General news
Treasury Market Outlook: yields are dropped on risk-off flows »

Treasury Market Outlook:…

SEE

Sealed Air

$32.41

-1.05 (-3.14%)

07:29
12/14/18
12/14
07:29
12/14/18
07:29
Upgrade
Sealed Air rating change  »

Sealed Air upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$247.71

2.27 (0.92%)

07:27
12/14/18
12/14
07:27
12/14/18
07:27
Recommendations
Adobe analyst commentary  »

Adobe valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COST

Costco

$226.41

-1.41 (-0.62%)

07:25
12/14/18
12/14
07:25
12/14/18
07:25
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$137.58

-0.26 (-0.19%)

07:25
12/14/18
12/14
07:25
12/14/18
07:25
Conference/Events
Visa management to meet with Wedbush »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 29

    Jan

BECN

Beacon Roofing

$31.84

-0.22 (-0.69%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REG

Regency Centers

$62.26

0.06 (0.10%)

07:24
12/14/18
12/14
07:24
12/14/18
07:24
Downgrade
Regency Centers rating change  »

Regency Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DRGDF

Detour Gold

$0.00

(0.00%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$186.53

2.99 (1.63%)

, YUM

Yum! Brands

$93.49

3.02 (3.34%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Recommendations
McDonald's, Yum! Brands analyst commentary  »

JPMorgan calls…

MCD

McDonald's

$186.53

2.99 (1.63%)

YUM

Yum! Brands

$93.49

3.02 (3.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNN

National Retail Properties

$50.86

0.94 (1.88%)

07:18
12/14/18
12/14
07:18
12/14/18
07:18
Downgrade
National Retail Properties rating change  »

National Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRGDF

Detour Gold

$0.00

(0.00%)

07:16
12/14/18
12/14
07:16
12/14/18
07:16
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$3.60

-0.155 (-4.13%)

07:15
12/14/18
12/14
07:15
12/14/18
07:15
Hot Stocks
Bellicum Pharmaceuticals reports data from BPX-601 at ESMO-IO »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THG

Hanover Insurance

$109.52

-0.68 (-0.62%)

07:14
12/14/18
12/14
07:14
12/14/18
07:14
Conference/Events
Hanover Insurance management to meet with Buckingham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

BHC

Bausch Health

$23.65

-0.47 (-1.95%)

07:12
12/14/18
12/14
07:12
12/14/18
07:12
Upgrade
Bausch Health rating change  »

Bausch Health upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.